Bright Minds Biosciences Inc.
DRUG
Classement en actions
#12818
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Prix de l'action
$52.46
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$517.47M
Changement (1 jour)
2.26%
Changement (1 an)
-20.81%
Pays
US
Échange Bright Minds Biosciences Inc. (DRUG)
Catégorie
Healthcare
Capitalisation boursière de Bright Minds Biosciences Inc.(DRUG)
Capitalisation boursière: $517.47M
En October 2026, Bright Minds Biosciences Inc. a une capitalisation boursière de $517.47M. Cela fait de Bright Minds Biosciences Inc. la 12818th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Bright Minds Biosciences Inc. du 2021 au 2026
DRUG par rapport au top 5 des plus populaires stocks
